Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Horwitz, Mitchell E  [Clear All Filters]
Journal Article
Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, Chute JP, Morris A, McDonald C, Waters-Pick B, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, Martínez C, García-Calderón C, Jiménez-León MReyes, Bermúdez-Rodríguez MAránzazu, López-Corral L, Triguero A, Onstad L, et al. Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials. Clin Cancer Res. 2023:OF1-OF11.
Poe JC, Fang J, Zhang D, Lee MR, DiCioccio RA, Su H, Qin X, Zhang JY, Visentin J, Bracken SJ, et al. Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD. JCI Insight. 2023.
Lin C, DiCioccio RA, Haykal T, McManigle WC, Li Z, Anand SM, Poe JC, Bracken SJ, Jia W, Alyea EP, et al. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease: SYK Inhibition in Chronic GVHD. Transplant Cell Ther. 2022.
Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, et al. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Transplant Cell Ther. 2023.
Cardones AR, Sullivan KM, Green C, Chao NJ, Rowe-Nichols K, Bañez LL, Burton CS, Horwitz ME, Long GD, Rao CL, et al. Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatol. 2019.
Allen JL, Tata PV, Fore MS, Wooten J, Rudra S, Deal AM, Sharf A, Hoffert T, Roehrs PA, Shea TC, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014.
Szabolcs P, Mazor RD, Yackoubov D, Levy S, Stiff P, Rezvani A, Hanna R, Wagner J, Keating A, Lindemans CA, et al. Immune Reconstitution Profiling Suggests Antiviral Protection After Transplantation with Omidubicel: a Phase 3 Substudy. Transplant Cell Ther. 2023.
Bracken SJ, Suthers A, DiCioccio RA, Su H, Anand S, Poe JC, Jia W, Visentin J, Basher F, Jordan CZ, et al. Heightened TLR7 Primes BCR-Activated Cells in Chronic Graft-Versus-Host Disease for Effector Functions. Blood Adv. 2023.
Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LPiu, et al. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel Versus Umbilical Cord Blood. Transplant Cell Ther. 2022.
Lew MV, Ren Y, Lowder YP, Siamakpour-Reihani S, Ramalingam S, Romero KM, Thompson JC, Bohannon LM, McIntyre J, Tang H, et al. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplant Candidates Ages 18-80 Years. Transplant Cell Ther. 2022.
Hussaini SMQasim, Ren Y, Racioppi A, Lew MV, Bohannon L, Johnson E, Li Y, Thompson JC, Henshall B, Darby M, et al. Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis. JCO Oncol Pract. 2023:OP2300243.
Horwitz ME. Ex Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation. Curr Hematol Malig Rep. 2015.
Smith P, Thompson JC, Perea E, Wasserman B, Bohannon L, Racioppi A, Choi T, Gasparetto C, Horwitz ME, Long G, et al. Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biol Blood Marrow Transplant. 2020.
Horwitz ME. Blood stem cell grafts: frozen is fine, but fresh is best. Blood Adv. 2023;7(19):5994-5995.